The pursuit of effective weight management solutions is a significant public health concern. While medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have garnered considerable attention for their role in weight loss, a recent real-world study suggests that bariatric surgery may offer substantially more profound and sustained results. Research presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting indicates that surgical interventions like sleeve gastrectomy and gastric bypass can lead to approximately five times greater weight loss than these widely used injectable medications over a two-year timeframe.
Comparing Weight Loss Outcomes: Surgery vs. GLP-1 Medications
The study, conducted by researchers at NYU Langone Health and NYC Health + Hospitals, analyzed data from a large cohort of patients. Over two years, individuals who underwent bariatric surgery achieved an average weight loss of 58 pounds. In stark contrast, patients prescribed GLP-1 medications for at least six months lost an average of only 12 pounds. This translates to a total weight loss of 24% for surgery patients compared to 4.7% for those using medication.
Even when examining patients who remained on GLP-1 therapy continuously for a full year, the average weight loss reached just 7%, a figure still considerably lower than the outcomes observed with surgical procedures. These findings underscore a critical difference between the controlled environments of clinical trials and the complexities of real-world patient care.
Real-World Effectiveness vs. Clinical Trial Data
Lead author Avery Brown, MD, a surgical resident at NYU Langone Health, commented on the disparity, noting, "Clinical trials show weight loss between 15% to 21% for GLP-1s, but this study suggests that weight loss in the real world is considerably lower even for patients who have active prescriptions for an entire year. We know as many as 70% of patients may discontinue treatment within one year." This observation points to potential challenges in long-term adherence and the impact of real-world factors on medication efficacy.
Dr. Brown further advised, "GLP-1 patients may need to adjust their expectations, adhere more closely to treatment, or opt for metabolic and bariatric surgery to achieve desired results." The study highlights that factors such as managing side effects, navigating costs, and maintaining consistent treatment regimens can significantly influence the effectiveness of medication-based weight loss strategies in everyday practice.
Methodology: How the Study Evaluated Treatment Options
To conduct this comparative analysis, researchers meticulously reviewed electronic medical records from patients treated between 2018 and 2024 within the NYU Langone Health and NYC Health + Hospitals systems. The study included participants with a body mass index (BMI) of 35 or higher who had either undergone bariatric surgery (specifically sleeve gastrectomy or Roux-en-Y gastric bypass) or had been prescribed injectable semaglutide or tirzepatide.
The research team employed advanced statistical methods, including average treatment effect weighting, to account for potential confounding variables such as age, initial BMI, and the presence of co-morbidities. This rigorous approach allowed for a more accurate comparison of outcomes between the surgical and medication groups. The study received support from the NYU CTSA grant KL2 TR001446, funded by the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH).
| Treatment Group | Average Weight Loss (lbs) | Percentage of Total Weight Loss |
|---|---|---|
| Bariatric Surgery (Sleeve Gastrectomy/Gastric Bypass) | 58 | 24% |
| GLP-1 Medications (Semaglutide/Tirzepatide) - 6+ months | 12 | 4.7% |
| GLP-1 Medications (Continuous for 1 year) | ~8.4 (estimated 7%) | 7% |
Note: The 7% weight loss for continuous GLP-1 therapy over one year is an estimation based on the article's statement that it reached only 7%, implying a slightly lower absolute pound loss than the 6-month group if the duration extended significantly beyond 6 months. The article states "Even among patients who stayed on GLP-1 therapy continuously for a full year, average weight loss reached only 7%."
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Future Directions and Treatment Considerations
Senior author Karan R. Chhabra, MD, MSc, a bariatric surgeon and Assistant Professor at NYU Grossman School of Medicine, outlined future research priorities. "In future studies we will aim to identify what healthcare providers can do to optimize GLP-1 outcomes, identify which patients are better treated with bariatric surgery versus GLP-1s, and determine the role out-of-pocket costs play in treatment success," he stated.
The widespread adoption of GLP-1 drugs is evident, with approximately 12% of Americans reporting past use and 6% currently using them. However, persistence remains a significant hurdle. Recent data indicates that over half of patients with overweight or obesity (53.6%) discontinue GLP-1 therapy within one year, a figure that escalates to 72.2% by the two-year mark. This high discontinuation rate can limit the long-term benefits of these medications.
Conversely, bariatric surgery, despite its proven effectiveness, remains underutilized. The ASMBS reported over 270,000 metabolic and bariatric procedures in 2023, representing only about 1% of eligible individuals. This suggests a substantial unmet need for more definitive weight management solutions.
The Role of Health Tracking with Shotlee
For individuals navigating complex weight management journeys, whether with medication or considering surgery, consistent tracking of progress, symptoms, and adherence is crucial. Tools like Shotlee can empower patients by providing a centralized platform to monitor weight changes, record medication doses, log side effects, and track dietary intake. This detailed health data can be invaluable for discussions with healthcare providers, enabling more informed treatment decisions and personalized care plans. By understanding individual responses and challenges, patients and clinicians can work together to optimize outcomes and address barriers to success.
Obesity: A Persistent Public Health Challenge
Obesity continues to be a major health crisis in the United States, affecting 40.3% of adults, with severe obesity impacting an additional 9.4%, according to the CDC. The health implications of excess weight are far-reaching, contributing to impaired immune function, chronic inflammation, and an elevated risk of numerous serious conditions, including cardiovascular disease, stroke, type 2 diabetes, and certain types of cancer. Addressing obesity effectively requires a comprehensive approach that considers all available treatment modalities.
ASMBS President Ann M. Rogers, MD, FACS, FASMBS, who was not involved in the study, emphasized the comparative efficacy: "While both patient groups lose weight, metabolic and bariatric surgery is much more effective and durable. Those who get insufficient weight loss with GLP-1s or have challenges complying with treatment due to side effects or costs, should consider bariatric surgery as an option or even in combination." This perspective highlights the importance of personalized treatment pathways in achieving sustainable weight loss and improving overall health.
Practical Takeaways
- Bariatric surgery demonstrated significantly higher and more sustained weight loss (24% over two years) compared to GLP-1 medications (4.7% over two years) in a real-world study.
- Real-world effectiveness of GLP-1s may be lower than clinical trial results due to factors like adherence, side effects, and cost.
- A high percentage of patients discontinue GLP-1 therapy within one to two years.
- Bariatric surgery remains underutilized despite its superior outcomes for eligible patients.
- Patients experiencing insufficient weight loss or treatment challenges with GLP-1s should discuss bariatric surgery as a potential option with their healthcare provider.
- Utilizing health tracking tools like Shotlee can support patients by monitoring progress, symptoms, and adherence, aiding in personalized care.
Conclusion
The findings from the NYU Langone Health and NYC Health + Hospitals study offer critical insights into the comparative effectiveness of bariatric surgery and GLP-1 medications for weight management. While GLP-1s have provided a valuable new therapeutic avenue, this research suggests that for individuals seeking substantial and durable weight loss, bariatric surgery remains a more potent option in real-world settings. The study underscores the need for comprehensive patient counseling, realistic expectation setting, and personalized treatment planning that considers the full spectrum of available interventions, including the potential benefits of surgery for those who may not achieve their goals with medication alone.
